Modern glucose-lowering treatment effect on bone remodeling in experimental diabetes mellitus and surgical menopause

Pharmacological correction of experimentally induced osteoporosis complicated by type 2 diabetes mellitus

BACKGROUND: Osteoporosis remains one of the most important medical problems worldwide with significant economic consequences. The development of new drugs based on unique biologically active compounds can contribute significantly to osteoporosis management. AIM: To evaluate the osteogenesis processes by evaluating bone-remodeling markers in the blood serum during the treatment of experimental osteoporosis complicated by type 2 diabetes mellitus. MATERIALS AND METHODS: The study was performed on an experimental model of osteoporosis, followed by the induction of type 2 diabetes mellitus, using biochemical methods to analyze markers of osteoporosis in the blood serum. RESULTS: The results of the analysis of bone remodeling markers revealed that the antiosteoporotic activity of a composite preparation based on succinic acid salts is dependent on glucose metabolism disorders such as diabetes mellitus. The high efficacy of the new drug in monotherapy and combination with vitamin D3 in the activation of osteogenesis in experimental osteoporosis was balanced by impaired metabolic processes in type 2 diabetes mellitus. CONCLUSIONS: The results indicate the dependence of the pharmacological effectiveness of the antiosteoporosis agent on metabolic disorders, such as type 2 diabetes mellitus, in female rats with experimental osteoporosis.